J&J's AKEEGA Approval Marks New Era for Prostate Cancer Treatment

HORSHAM, PA – December 12, 2025 – The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's AKEEGA®, a dual-action tablet, for patients with a specific and aggressive form of prostate cancer, heralding a significant advancement in the field of precision oncology. The approval, announced today, positions AKEEGA® as the first precision medicine combination treatment for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).

This landmark decision is built on the strength of the Phase 3 AMPLITUDE study, which demonstrated that the combination therapy of niraparib and abiraterone acetate, administered as a single tablet with prednisone, reduced the risk of radiographic disease progression or death by a remarkable 54 percent compared to the current standard of care. For patients grappling with this genetically defined, aggressive cancer, the approval offers a powerful new therapeutic option and a renewed sense of hope.

A Targeted Strike Against an Aggressive Foe

Metastatic castration-sensitive prostate cancer refers to cancer that has spread beyond the prostate but still responds to hormone therapy aimed at lowering testosterone levels. However, a subset of these patients carries mutations in the BRCA2 gene, a genetic alteration more commonly associated with breast and ovarian cancer. In men, these mutations are linked to a more aggressive disease course, faster progression, and ultimately, poorer survival outcomes. Research indicates that patients with BRCA mutations can experience disease progression approximately 50 percent faster than those without, creating a significant unmet medical need.

Until now, treatment for this group largely followed protocols for the broader mCSPC population, without addressing the underlying genetic driver of their aggressive cancer. AKEEGA® changes that paradigm. It combines two distinct mechanisms in one tablet: niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor. PARP inhibitors work by exploiting a weakness in cancer cells with BRCA mutations, preventing them from repairing their own DNA and leading to cell death. Abiraterone acetate, already a staple in prostate cancer treatment, works by blocking the production of androgens that fuel cancer growth. The combination delivers a powerful one-two punch specifically tailored to the biology of BRCA-mutated tumors.

"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the mutation," said Dr. Bradley McGregor, Director of Clinical Research for the Lank Center of Genitourinary Oncology at Dana-Farber Cancer Institute. "AMPLITUDE is the first study to show that this precision medicine combination of a PARP inhibitor with an androgen receptor pathway inhibitor delays both radiographic and symptomatic disease progression."

Decoding the Decisive AMPLITUDE Data

The FDA's decision rests on the robust results from the global, randomized, double-blind AMPLITUDE clinical trial. The study's primary endpoint was radiographic progression-free survival (rPFS)—the length of time a patient lives without their cancer showing signs of growing on medical scans. In the BRCA2-mutated subgroup, the results were striking. The median rPFS for patients on the AKEEGA® regimen was not yet reached, as many were still responding to treatment, compared to 26 months for those receiving the standard of care (placebo plus abiraterone acetate and prednisone).

Beyond just slowing tumor growth, the therapy also had a tangible impact on patient well-being. A key secondary endpoint, time to symptomatic progression (TSP), was significantly prolonged. Patients receiving AKEEGA® saw a 59 percent reduction in the risk of their symptoms worsening, a critical factor for maintaining quality of life. The safety profile of the combination therapy was consistent with the known side effects of each drug individually. The most common serious adverse reactions included anemia, hypertension, and fatigue, which physicians are already experienced in managing from the monotherapies.

Crucially, the study's findings underscore the importance of patient selection. While the trial enrolled patients with a variety of homologous recombination repair (HRR) gene alterations, exploratory analysis showed the benefit was most pronounced and statistically significant in those with BRCA2 mutations. This highlights a pivotal shift in clinical practice: genetic testing is no longer just for determining risk but is now an essential tool for guiding treatment decisions in mCSPC.

Reshaping the Market and J&J’s Oncology Strategy

This approval is a major strategic victory for Johnson & Johnson, significantly expanding the market for AKEEGA®, which was previously approved for a later stage of the disease, metastatic castration-resistant prostate cancer (mCRPC). By moving into the earlier, castration-sensitive setting, the company can offer its targeted therapy to a larger patient population at a critical juncture in their treatment journey.

The global prostate cancer therapeutics market, projected to exceed $25 billion by 2029, is a highly competitive space. Johnson & Johnson has long been a leader with foundational drugs like ZYTIGA® (abiraterone acetate) and ERLEADA® (apalutamide). The approval of AKEEGA® for mCSPC fortifies its position, demonstrating a commitment to precision oncology and addressing niche, high-need populations that competitors have yet to reach with a targeted combination therapy.

"This expanded indication for AKEEGA reflects our commitment to push the boundaries of science and deliver more personalized, effective treatment options across the prostate cancer continuum," said Mahadi Baig, M.D., M.H.C.M., Vice President at Johnson & Johnson Innovative Medicine. "Supported by strong clinical data, AKEEGA is now the first and only PARP-based precision medicine combination treatment in BRCA2-mutated mCSPC, offering patients hope for more time with a new way to potentially delay their cancer from progressing."

The Path Forward: Patient Access and the Primacy of Testing

For patients and their families, the approval of AKEEGA® is a monumental step forward, but the focus now shifts to practical considerations of access and affordability. As a specialty medication, AKEEGA® comes with a significant price tag, and navigating insurance coverage will be a key hurdle for many.

Recognizing this, Johnson & Johnson has established its J&J withMe patient support program. This comprehensive service offers dedicated nurse navigators to guide patients and provides financial assistance options. Eligible, commercially insured patients may benefit from a savings program that can reduce out-of-pocket costs to as little as $0 per month, up to an annual maximum. For uninsured or underinsured patients, the Johnson & Johnson Patient Assistance Program may provide the medication at no cost based on income and other eligibility criteria.

Ultimately, the efficacy of AKEEGA® hinges on identifying the right patients. This approval elevates the importance of genetic testing for men diagnosed with metastatic prostate cancer. As the treatment landscape evolves to include more biomarker-driven therapies, routine testing for mutations like BRCA2 will become an indispensable part of the standard of care, ensuring that groundbreaking treatments like AKEEGA® reach the patients who stand to benefit most.